# Safety Study of SEA-CD40 in Cancer Patients

> **NCT02376699** · PHASE1 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 159 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Hodgkin Disease
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Melanoma
- Neoplasm Metastasis
- Neoplasms, Head and Neck
- Neoplasms, Squamous Cell
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer Metastatic
- Non-small Cell Carcinoma
- Squamous Cell Cancer
- Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Neoplasm
- Lymphoma, Non-Hodgkin
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Intravenous (IV) SEA-CD40
- **DRUG:** Pembrolizumab
- **DRUG:** Subcutaneous (SC) SEA-CD40
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02376699
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-28
- **Primary completion:** 2023-03-06
- **Final completion:** 2023-04-14
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** Study closed due to portfolio prioritization
- **Last updated:** 2023-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02376699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02376699, "Safety Study of SEA-CD40 in Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02376699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*